KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Plus Paclitaxel ± Bevacizumab, Approved for Certain Adults with PD-L1+ (CPS ≥1) Platinum-Resistant Ovarian Carcinoma as Second or Third Line Treatment

Core Viewpoint - Merck has received FDA approval for KEYTRUDA® and KEYTRUDA QLEX™ for treating adults with PD-L1+ platinum-resistant epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer [1] Group 1: Product Approval - The FDA approved KEYTRUDA® (pembrolizumab) for the treatment of adults with PD-L1+ (Combined Positive Score [CPS] 1) [1] - KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) plus paclitaxel, with or without bevacizumab, is also approved for the same indication [1]